overweight / obesity q15y ≥ 5.7% dementia hypertension ≥ 140 mg/dL q1y women age 55- 64 y.o. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk diabetes Timed up and go test tobacco use breast cancer insufficient evidence for screening cardiovascular disease anxiety ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors q2y q5y statin ≥ 126 mg/dL lung cancer depression 2 doses, 2-6 months apart 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor ≤ q2y ovarian cancer 3% multidose initial series, then 1 dose at 2-6 months q3y 65 y.o. 60 y.o. ≥ 100 mg/dL 1 dose; 2 doses (2-6 months apart) if immunocomp tamoxifen dyslipidemia q1-2y mammogram based on life expectancy / health status HIV Tyrer- Cuzick model 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor 40-59 y.o., ASCVD ≥ 10%, low bleeding risk < 60 y.o. aspirin Gail model raloxifene 52 y.o. ≥ 20% aromatase inhibitors 50 y.o. herpes zoster q1y mammogram Fracture Risk Assessment Tool cervical cancer 75 y.o. community- dwelling, postmenopausal women 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors pneumococcal Hepatitis B ≥ 200 mg/dL 40 y.o. hormone therapy PREVENT equation colorectal cancer Hepatitis C ≥ 6.5% overweight / obesity q15y ≥ 5.7% dementia hypertension ≥ 140 mg/dL q1y women age 55- 64 y.o. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk diabetes Timed up and go test tobacco use breast cancer insufficient evidence for screening cardiovascular disease anxiety ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors q2y q5y statin ≥ 126 mg/dL lung cancer depression 2 doses, 2-6 months apart 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor ≤ q2y ovarian cancer 3% multidose initial series, then 1 dose at 2-6 months q3y 65 y.o. 60 y.o. ≥ 100 mg/dL 1 dose; 2 doses (2-6 months apart) if immunocomp tamoxifen dyslipidemia q1-2y mammogram based on life expectancy / health status HIV Tyrer- Cuzick model 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor 40-59 y.o., ASCVD ≥ 10%, low bleeding risk < 60 y.o. aspirin Gail model raloxifene 52 y.o. ≥ 20% aromatase inhibitors 50 y.o. herpes zoster q1y mammogram Fracture Risk Assessment Tool cervical cancer 75 y.o. community- dwelling, postmenopausal women 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors pneumococcal Hepatitis B ≥ 200 mg/dL 40 y.o. hormone therapy PREVENT equation colorectal cancer Hepatitis C ≥ 6.5%
(Print)
overweight / obesity
q15y
≥ 5.7%
dementia
hypertension
≥ 140 mg/dL
q1y
women age 55-64 y.o.
40-70 y.o., ASCVD ≥ 10%, low bleeding risk
diabetes
Timed up and go test
tobacco use
breast cancer
insufficient evidence for screening
cardiovascular disease
anxiety
≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
q2y
q5y
statin
≥ 126 mg/dL
lung cancer
depression
2 doses, 2-6 months apart
40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
≤ q2y
ovarian cancer
3%
multidose initial series, then 1 dose at 2-6 months
q3y
65 y.o.
60 y.o.
≥ 100 mg/dL
1 dose; 2 doses (2-6 months apart) if immunocomp
tamoxifen
dyslipidemia
q1-2y mammogram based on life expectancy / health status
HIV
Tyrer-Cuzick model
40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
40-59 y.o., ASCVD ≥ 10%, low bleeding risk
< 60 y.o.
aspirin
Gail model
raloxifene
52 y.o.
≥ 20%
aromatase inhibitors
50 y.o.
herpes zoster
q1y mammogram
Fracture Risk Assessment Tool
cervical cancer
75 y.o.
community-dwelling, postmenopausal women
40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
pneumococcal
Hepatitis B
≥ 200 mg/dL
40 y.o.
hormone therapy
PREVENT equation
colorectal cancer
Hepatitis C
≥ 6.5%
